Takeda Pharmaceutical Co. $TAK Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC decreased its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 31.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 76,483 shares of the company’s stock after selling 35,614 shares during the quarter. Corient Private Wealth LLC’s holdings in Takeda Pharmaceutical were worth $1,192,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Private Trust Co. NA lifted its position in Takeda Pharmaceutical by 84.7% during the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after acquiring an additional 783 shares during the period. Parkside Financial Bank & Trust increased its holdings in shares of Takeda Pharmaceutical by 192.2% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after purchasing an additional 1,684 shares during the period. SHP Wealth Management purchased a new position in shares of Takeda Pharmaceutical in the fourth quarter worth about $42,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Takeda Pharmaceutical by 313.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after purchasing an additional 2,328 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Takeda Pharmaceutical by 56.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after purchasing an additional 1,292 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of NYSE TAK opened at $15.96 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.60 and a current ratio of 1.09. The firm has a fifty day moving average of $16.09 and a 200 day moving average of $16.84. The firm has a market cap of $50.78 billion, a PE ratio of 40.91 and a beta of -0.07. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. The business had revenue of $6.90 billion for the quarter. As a group, research analysts predict that Takeda Pharmaceutical Co. will post 0.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TAK has been the topic of several recent research reports. Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Sunday. Zacks Research downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Monday. Finally, Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Takeda Pharmaceutical currently has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.